Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Verrica Pharmaceuticals ( (VRCA) ) has provided an announcement.
On June 5, 2025, Verrica Pharmaceuticals held its annual stockholders meeting where four proposals were considered. All three director nominees were elected, executive compensation was approved, KPMG LLP’s appointment as the accounting firm was ratified, and a potential reverse stock split was authorized, reflecting strong shareholder support for the company’s strategic decisions.
The most recent analyst rating on (VRCA) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Verrica Pharmaceuticals stock, see the VRCA Stock Forecast page.
Spark’s Take on VRCA Stock
According to Spark, TipRanks’ AI Analyst, VRCA is a Neutral.
Verrica Pharmaceuticals faces serious financial challenges, including declining revenues and negative equity, which heavily weigh down the stock score. Despite these issues, positive developments in sales growth and clinical progress partially offset the financial concerns. Technical indicators show some short-term positive momentum, although longer-term trends remain bearish. The earnings call provided a balanced view of both progress and ongoing challenges.
To see Spark’s full report on VRCA stock, click here.
More about Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc. operates within the pharmaceutical industry, focusing on developing and commercializing dermatological treatments. The company aims to address unmet needs in skin diseases, leveraging innovative therapeutic solutions.
Average Trading Volume: 388,274
Technical Sentiment Signal: Sell
Current Market Cap: $49.12M
See more data about VRCA stock on TipRanks’ Stock Analysis page.